flumazenil has been researched along with 22q11.2 Deletion Syndrome in 1 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mori, T | 1 |
| Mori, K | 1 |
| Fujii, E | 1 |
| Toda, Y | 1 |
| Miyazaki, M | 1 |
| Harada, M | 1 |
| Kagami, S | 1 |
1 other study available for flumazenil and 22q11.2 Deletion Syndrome
| Article | Year |
|---|---|
Neuroradiological and neurofunctional examinations for patients with 22q11.2 deletion.
Topics: Case-Control Studies; Child; Child, Preschool; DiGeorge Syndrome; Electroencephalography; Epilepsy; | 2011 |